Overview
Updated 14 Jul 2026
Elias Jabbour, M.D., is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,365 publications with 56,927 citations (h-index 115), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 38 registered clinical trials, industry payments reported by 43 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Acute Myeloid Leukemia Research
- 38 registered trials on ClinicalTrials.gov
- Open Payments reporting from 43 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 228 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 808.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 38 registered studies on ClinicalTrials.gov. The most recent:
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 1Not, yet, recruitingNCT07283640 - Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2Not, yet, recruitingNCT07192237 - Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2Not, yet, recruitingNCT07178912
Industry payments
Updated 14 Jul 2026
43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202534 payments$51,949openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20254 payments$27,110openpaymentsdata.cms.gov ↗
- Hikma Pharmaceuticals USAProgram year20259 payments$23,787openpaymentsdata.cms.gov ↗
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.
American journal of hematology
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03
- 04Ibrutinib and Venetoclax for First-Line Treatment of CLL504 citations2019
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Board Certified
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Board Certified
American Board of Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nature.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →karger.com ↗
- Editorial Board Member
Blood Advances -- claimed on MD Anderson bio but NOT found on ASH Publications' own official Blood Advances editorial board listing after 3 verification attempts …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
- King Hussein Cancer Award for Cancer Research
Lifetime Achievement (International Physician category)
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kinghusseincanceraward.jo ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniusj.org ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Media & interviewspress, podcasts and appearances
- OncLive On Air podcast/video series -- multiple appearances discussing CML
ALL, olverembatinib, ponatinib (recurring contributor)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- ResearchGate
researchgate.net/lab/Elias-Jabbour-Lab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Elias-J-Jabbour-2145453855
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/blood-cancers-today_elias-jabbour-md-recognizes-blood-cancer-activity-6977735433006850048-NqKJ
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/societyofhematologiconcology_elias-jabbour-md-talks-about-obe-cel-ash-activity-7279908134733692928-eUz0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
bloodcancerstoday.com/author/elias-jabbour-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
- 5,579
- publications
- 233
- h-index
- 24
- trials
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
- 1,905
- publications
- 187
- h-index
- 1
- trial
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials